These systemic inflammatory changes also interact with tumor-intrinsic molecular drivers, including EGFR, KRAS, ALK, and TP53 mutations, influencing immune evasion, disease progression, and response to immune checkpoint inhibitors [11]. This evidence concerns the gene KRAS and neoplasm.